Objective The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic
arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 &-2) but …

Objective. Biologic agents with different mechanisms of action [inhibitors of tumor necrosis
factor-α (TNF-α), interleukin (IL)-12/23, and IL-17] showed efficacy in randomized controlled …

Objective To compare improvement in pain and physical function for patients treated with
baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised …

Although psoriasis and psoriatic arthritis (PsA) have been classically considered to be
diseases of the skin and joints, respectively, emerging evidence suggests that a combination …

Introduction Secukinumab and adalimumab are approved for adults with active psoriatic
arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching …

Objectives To compare treatment retention and response to secukinumab vs adalimumab,
including the other four TNF inhibitors (TNFi) as comparators, in PsA. Methods All patients …

PURPOSE Larotrectinib, a highly specific tropomyosin receptor kinase (TRK) inhibitor,
previously demonstrated high response rates in single-arm trials of patients with TRK fusion …

Background Plaque psoriasis has significant impact on patients' quality of life. Topical
therapy is considered the treatment mainstay for mild‐to‐moderate disease according to …

Psoriatic arthritis (PsA) is a chronic multi-faceted immune-mediated systemic disorder,
characterized by articular, cutaneous, enthesis, nail and spine involvement. Articular …

Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic
arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient …